Literature DB >> 18701419

Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.

Andreas Calatzis1, Dirk Peetz, Sylvia Haas, Michael Spannagl, Karin Rudin, Marianne Wilmer.   

Abstract

The prothrombinase-induced clotting time assay (PiCT, Pentapharm, Basel, Switzerland) is a clotting assay sensitive to factor Xa and factor IIa inhibitors. It is based on the addition of factor Xa and snake venom RVV-V (Russell viper venom factor V activator) specifically activating factor V and phospholipids to platelet-poor plasma. Following an incubation time, the mixture is recalcified and the clotting time is determined. An almost linear dose-response and high sensitivity of the assay for unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), r-hirudin, and argatroban was found. Fondaparinux showed a nonlinear dose-response. By using ex vivo samples, the following Pearson correlation coefficients were found: r=0.85 between amidolytic anti-Xa and PiCT for 120 LMWH and 24 control samples; r=0.86 between amidolytic anti-Xa activity and PiCT for 68 UFH and 24 control samples; and r=0.94 between ECT and PiCT for 38 hirudin samples. Thus, PiCT is a promising assay for the monitoring of anticoagulants inhibiting factor Xa and/or factor IIa.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18701419     DOI: 10.1309/Q0G21Y26UR0UHQ1A

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  2 in total

Review 1.  Monitoring of direct anticoagulants.

Authors:  Susanne Lison; Michael Spannagl
Journal:  Wien Med Wochenschr       Date:  2011-02

2.  A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.

Authors:  Jeanne Mendell; Robert J Noveck; Minggao Shi
Journal:  Br J Clin Pharmacol       Date:  2013-04       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.